Atley Solutions Secures $5M Investment to Revolutionize At-211 Radiopharmaceutical Manufacturing

Atley Solutions is proud to announce its successful funding round, having raised $5,000,000 to accelerate its mission as the global leader in commercial products and services dedicated to the development, clinical evaluation, and commercialization of At-211 radiopharmaceuticals. This significant capital injection is a testament to the strong investor confidence in Atley’s innovative approach and its proven track record in transforming the landscape of radiopharmaceutical development. Established as a pioneer in the field, Atley Solutions continues to push boundaries with cutting-edge technology such as the Atley C100 – the world’s only commercial module that automates the manufacturing of At-211 radiopharmaceuticals. This breakthrough innovation not only positions the company as the forefront provider of automated solutions in the industry but also ensures enhanced efficiency and quality in production, setting new standards for safety and reliability. Beyond its flagship product, Atley Solutions offers comprehensive non-clinical radiopharmaceutical development services and serves as a key supplier of At-211, making it an indispensable partner for clinical and research organizations worldwide. The recent funding will be strategically utilized to expand research and development capabilities, enhance manufacturing processes, and broaden the global reach of the company’s solutions. With an unwavering commitment to innovation in radiopharmaceuticals, Atley Solutions is poised to significantly impact research, clinical trials, and patient care on an international scale. As the company embarks on this exciting new phase, it remains dedicated to advancing the science of radiopharmaceuticals, ensuring that groundbreaking treatments and life-saving technologies are accessible to healthcare providers and patients around the globe.